Low hemoglobin levels: Influence on tumor biology and radiotherapy treatment outcome

European Journal of Cancer, Supplement

Volumn 2, Issue 2, 2004, Pages 3-10

  Dunst, J ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Anemia; Angiogenesis; Epoetin alfa; Intratumoral hypoxia; Radiotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HEMOGLOBIN; MELPHALAN; MITOMYCIN C; OXYGEN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN; VINBLASTINE;

ANEMIA; ANGIOGENESIS; BIOLOGY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG RESPONSE; EXPERIMENT; GENE MUTATION; GENETIC ANALYSIS; GENETIC STABILITY; GENOME; HUMAN; HYPOXIA; METASTASIS; MOUTH CARCINOMA; NONHUMAN; OROPHARYNX CARCINOMA; OXYGEN TRANSPORT; OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR; TUMOR CELL;

EID: 2442597357     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00102-2     Document Type: Conference Paper

References (49)

1. Molls M., Stadler P., Becker A., Feldman H.J., Dunst J. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther. Onkol. 174:(Suppl. 4):1998;13-16
2. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression angiogenesis, metastasis and therapeutic exploitation. Eur. J. Cancer. 36:2000;1649-1660
3. Höckel M., Schlenger K., Aral B., Mitze M., Schäffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56:1996;4509-4515
4. Vaupel P., Briest S., Höckel M. Hypoxia in breast cancer pathogenesis, characterization and biological/therapeutic implications. Wien Med. Wschr. 152:2002;334-342
5. Kelleher D.K., Matthiensen U., Thews O., Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res. 56:1996;4728-4734
6. Kelleher D.K., Thews O., Vaupel P. Can erythropoietin improve tumor oxygenation? Strahlenther. Onkol. 174:(Suppl. IV):1998;20-23
7. Lavey R.S., McBride W.H. Influence of hematocrit on tumor oxygenation and sensitivity to radiation. Eur. J. Cancer. 29A:1993;S216
8. Lavey R.S. Clinical trial experience using erythropoietin during radiation therapy. Strahlenther. Onkol. 174:(Suppl. IV):1998;24-30
9. Vaupel P., Thews O., Hoeckel M. Treatment resistance of solid tumors. Med. Oncol. 18:2001;243-259
10. Becker A., Stadler P., Lavey R.S., et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 46:2000;459-466
11. 2 tension measurements. Cancer Res. 51:1991;3316-3322
12. Thews O., Vaupel P. Tumor hypoxia and anemia implications for the outcome of radiotherapy and chemotherapy. Focus Anaemia Cancer. 2:2001;59-65
13. Fyles A.W., Milosevic M., Wong R., et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48:1998;149-156
14. 2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother. Oncol. 53:1999;99-104
15. Vaupel P., Thews O., Kelleher D.K., Hoeckel M. Oxygenation of human tumors the Mainz experience. Strahlenther. Onkol. 174:(Suppl. IV):1998;6-12
16. 2 during early radiotherapy in cervical cancers improved local control in primarily hypoxic tumors with "reoxygenation" and the impact of hemoglobin. Int. J. Radiat. Oncol. Biol. Phys. 45:(Suppl. 1):1999;364. (abstr. 2168)
17. Höckel M., Vaupel P. Tumor hypoxia definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:2001;266-276
18. Höckel M., Vaupel P. Biological consequences of tumor hypoxia. Semin. Oncol. 28:(Suppl. 8):2001;36-41
19. Coquelle A., Toledo F., Stern S., Bieth A., Debatisse M. A new role for hypoxia in tumor progression induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol. Cell. 2:1998;259-265
20. Reynolds T.Y., Rockwell S., Glazer P.M. Genetic instability induced by the tumor microenvironment. Cancer Res. 56:1966;5754-5757
21. Yuan J., Glazer P.M. Mutagenesis induced by the tumor microenvironment. Mutat. Res. 400:1998;439-446
22. Rofstad E.K. Microenvironment-induced cancer metastasis. Int. J. Radiat. Biol. 76:2000;589-605
23. Yuan J., Narayanan L., Rockwell S., Glazer P.M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res. 60:2000;4372-4376
24. Graeber G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature. 379:1996;88-91
25. Hall EH, ed. Radiobiology for the Radiologist 4th ed. Philadelphia, PA, Lippincott, 1994.
26. Kumar P. Impact of anemia in patients with head and neck cancer. Oncologist. 5:(Suppl. 2):2000;13-18
27. Hollaender A., Stapleton G.E., Martin F.L. X-ray sensitivity of E. coli as modified by oxygen tension. Nature. 167:1951;103-104
28. Teicher B.A. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol. Oncol. Clin. North Am. 9:1995;475-506
29. Vaupel P., Höckel M. Tumor hypoxia and therapeutic resistance. Nowrousian M.R. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. 2002;127-146 Springer, Berlin, Germany
30. Durand R.E. Intermittent blood flow in solid tumors - an under-appreciated source of "drug resistance" Cancer Metast. Rev. 20:2001;57-61
31. Teicher B.A., Lazo J.S., Sartorelli A.C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41:1981;73-81
32. Teicher B.A., Holden S.A., Al-Achi A., et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FsallC murine fibrosarcoma. Cancer Res. 50:1990;3339-3344
33. Teicher B.A. Hypoxia and drug resistance. Cancer Metast. Rev. 13:1994;139-168
34. Weidner N., Carroll P.R., Flax J., Blumenfeld W., Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am. J. Pathol. 143:1993;401-409
35. Weidner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med. 324:1991;1-8
36. Mineta H., Miura K., Ogino T., et al. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br. J. Cancer. 83:2000;775-781
37. Smith B.D., Smith G.L., Carter D., Sasaki C.T., Haffty B.G. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J. Clin. Oncol. 18:2000;2046-2052
38. Klein M., Vignaud J.M., Hennequin V., et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 86:2001;656-658
39. Dunst J., Pigorsch S., Hänsgen G., et al. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther. Onkol. 175:1999;93-96
40. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer. 86:1999;1528-1536
41. Tarnawski R., Skladowski K., Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int. J. Radiat. Oncol. Biol. Phys. 38:1997;1007-1011
42. Egrie J.K., Strickland T.W., Lane J., et al. Characterization and biological effects of recombinant human erythropoietin. Immunobiology. 172:1986;213-224
43. Abels R. Erythropoietin for anemia in cancer patients. Eur. J. Cancer. 29A:(Suppl. 2):1993;S2-S8
44. Glaspy J., Bukowski R., Steinberg D., Taylor C., Tchekmedyian S., Vadhan-Raj S. for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J. Clin. Oncol. 15:1997;1218-1234
45. Demetri G.D., Kris M., Wade J., Degos L., Cella D. for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J. Clin. Oncol. 16:1998;3412-3425
46. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., Rapoport B. for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 19:2001;2865-2974
47. Gabrilove J.L., Cleeland C.S., Livingston R.B., Sarokhan B., Winer E., Einhorn L.H. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J. Clin. Oncol. 19:2001;2875-2882
48. Glaser C., Millesi W., Kornek G.V., et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int. J. Radiat. Oncol. Biol. Phys. 50:2001;705-715
49. Antonadou D., Cardamakis E., Puglisi M., Malamos N., Throuvalas N. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur. J. Cancer. 37:(Suppl. 6):2002;S144. (abstr 530)